Unlock stock picks and a broker-level newsfeed that powers Wall Street.

High Growth Tech Stocks To Watch In The US April 2025

In This Article:

As the U.S. market navigates a turbulent landscape marked by volatile trading sessions and fluctuating economic indicators, investors are closely watching the impact of ongoing tariff developments and bank earnings on major indices like the Dow Jones Industrial Average, which recently experienced significant swings. In such an environment, identifying high-growth tech stocks requires careful consideration of their resilience to macroeconomic pressures and potential for innovation amidst shifting trade policies.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

20.44%

29.79%

★★★★★★

TG Therapeutics

26.03%

37.60%

★★★★★★

Alkami Technology

20.46%

85.16%

★★★★★★

Travere Therapeutics

28.56%

65.75%

★★★★★★

Arcutis Biotherapeutics

25.76%

58.17%

★★★★★★

Alnylam Pharmaceuticals

22.73%

58.77%

★★★★★★

TKO Group Holdings

22.48%

25.17%

★★★★★★

AVITA Medical

28.21%

56.12%

★★★★★★

Lumentum Holdings

21.61%

120.49%

★★★★★★

Ascendis Pharma

32.36%

59.79%

★★★★★★

Click here to see the full list of 231 stocks from our US High Growth Tech and AI Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Arcturus Therapeutics Holdings

Simply Wall St Growth Rating: ★★★★★☆

Overview: Arcturus Therapeutics Holdings Inc. focuses on developing vaccines for infectious diseases and products targeting liver and respiratory rare diseases, with a market cap of $266.32 million.

Operations: The company generates revenue primarily from the research and development of medical applications, totaling $152.31 million.

Arcturus Therapeutics Holdings, despite a challenging fiscal year with a net loss widening to $80.94 million from $29.73 million, shows promise in its innovative vaccine development segment. The FDA's Fast Track Designation for ARCT-2304, a self-amplifying mRNA vaccine against influenza A H5N1, underscores its potential in addressing global health risks with cutting-edge technology. This recognition could expedite the development process and enhance communication with regulatory bodies, potentially positioning Arcturus at the forefront of pandemic response innovations. Meanwhile, revenue forecasts anticipate robust growth at 37% annually, outpacing the industry average significantly.

NasdaqGM:ARCT Revenue and Expenses Breakdown as at Apr 2025
NasdaqGM:ARCT Revenue and Expenses Breakdown as at Apr 2025

Bel Fuse

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Bel Fuse Inc. is a company that designs, manufactures, markets, and sells products for powering, protecting, and connecting electronic circuits with a market capitalization of $889.44 million.